QUANTA LITE MPO IGG (MYELOPEROXIDASE) TEST KIT

K981330 · Inova Diagnostics, Inc. · MOB · Jun 19, 1998 · Immunology

Device Facts

• Record ID: K981330
• Device Name: QUANTA LITE MPO IGG (MYELOPEROXIDASE) TEST KIT
• Applicant: Inova Diagnostics, Inc.
• Product Code: MOB · Immunology
• Decision Date: Jun 19, 1998
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5660
• Device Class: Class 2

Intended Use

An enzyme linked immunosorbant assay (ELISA) for the semiof autoantibodies to detection IgG quantitative myeloperoxidase(MPO). This test is to be used in conjunction with other clinical findings to aid in assessment of certain autoimmune vasculitides such as microscopic polyarteritis, and crescentic qlomerulonephritis.

Device Story

QUANTA Lite™ MPO IgG is an ELISA-based in vitro diagnostic test. It detects IgG autoantibodies against myeloperoxidase in human serum samples. The assay utilizes standard enzyme-linked immunosorbent assay principles to provide semi-quantitative results. It is intended for use in clinical laboratory settings by trained laboratory personnel. Results are interpreted by clinicians alongside other clinical findings to assist in the diagnosis and assessment of autoimmune vasculitides, specifically microscopic polyarteritis and crescentic glomerulonephritis.

Clinical Evidence

No clinical data provided in the document.

Technological Characteristics

Enzyme-linked immunosorbent assay (ELISA) for semi-quantitative detection of IgG autoantibodies. In vitro diagnostic device.

Indications for Use

Indicated for the semi-quantitative detection of IgG autoantibodies to myeloperoxidase (MPO) in human serum. Used as an aid in the assessment of autoimmune vasculitides, including microscopic polyarteritis and crescentic glomerulonephritis, in conjunction with other clinical findings.

Regulatory Classification

Identification

A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies).

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" written around the perimeter. Inside the circle is an abstract image of an eagle.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

## JUN 1 9 1998

Mr. Brys Myers Requlatory Affairs INOVA Diagnostics, Inc. 10180 Scripps Ranch Boulevard San Dieqo, California 92131-1234

Re : K981330 QUANTA Lite™ MPO IgG Trade Name: Regulatory Class: II Product Code: MOB Dated: April 9, 1998 Received: April 13, 1998

Dear Mr. Myers:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Reqister. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.

{1}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. TO determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number [phone] or at [phone] or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven Putman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure --------------------------------------------------------------------------------------------------------------------------------------------------------------------

{2}------------------------------------------------

| 11<br>1<br><br>charges and and any and the contraction of the collection of the colors of the colors of the colors of the colors of the colors of the colors of the colors of the colors of t | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|

| 510(k) Number (if known): | K981330 |
|---------------------------|----------------------|
| Device Name: | QUANTA Lite™ MPO IgG |

## Indications For Use:

An enzyme linked immunosorbant assay (ELISA) for the semiof autoantibodies to detection IgG quantitative myeloperoxidase(MPO). This test is to be used in conjunction with other clinical findings to aid in assessment of certain autoimmune vasculitides such as microscopic polyarteritis, and crescentic qlomerulonephritis.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Titus E. Martin

(Division Sign-Off)
Division of Clinical Laboratory Device K98/133d
510(k) Number

ಿ rescription Use_ (Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)